Sartorius SRT3.DE
Sartorius AG is a supplier of equipment and consumables for the pharmaceutical and biotechnology industry, specializing in bioprocessing and laboratory technologies. Sartorius shows moderate financial health with net debt of 4.01x EBITDA and an operating margin of 18%, but its valuation is demanding (P/E 94.17) and revenue growth is modest (3.1%), limiting its appeal.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Sartorius AG is a supplier of equipment and consumables for the pharmaceutical and biotechnology industry, specializing in bioprocessing and laboratory technologies. Sartorius shows moderate financial health with net debt of 4.01x EBITDA and an operating margin of 18%, but its valuation is demanding (P/E 94.17) and revenue growth is modest (3.1%), limiting its appeal.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.0 |
| Quality / Moat | 4.9 |
| Valuation | 2.9 |
| Growth | 5.1 |
| Dividend | 4.3 |
| Momentum | 6.0 |
| Risk & Context | 4.2 |
OVERALL SCORE: 4.5/10
Context and risks
Sartorius is a healthcare and biotech company based in Germany, with no direct exposure to commodities, interest rates, or relevant geopolitical tensions. The macro context does not materially affect its business.
News considered in the analysis
- Sartorius (XTRA:SRT3) Could Be 21% Below Fair Value On Dublin Training Push — Artículo de valoración de Simply Wall St. que sugiere un potencial alcista del 21%, pero es una opinión de analista, no un hecho material.
- Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost? — Noticia sobre competidores (Danaher, Bio-Rad) sin impacto directo en Sartorius; mero ruido sectorial.
- The 'Standout Performance' That Could Save Thermo Fisher, Danaher And Others — Artículo genérico sobre el sector de ciencias de la vida, sin información específica sobre Sartorius.
- Sartorius AG (SARTF) Q2 2026 Earnings Call Highlights: Strong Growth Amidst Market Challenges — Resultados del segundo trimestre con crecimiento sólido en un entorno difícil; ya comunicado y parcialmente descontado.
- Sartorius Aktiengesellschaft Q2 Earnings Call Highlights — Mismo evento que la noticia anterior, sin información adicional.
Verdict: Hold; the business quality is solid but the valuation offers no margin of safety.
Main risk: High leverage (Net Debt/EBITDA of 4.01) and demanding valuation (P/E 94.17) are the main risks, especially if growth does not accelerate.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →